Date: 2015-03-26
Type of information: R&D agreement
Compound: antibody-drug conjugates (ADCs), for multiple oncology targets
Company: Oncodesign (France) Synthon Biopharmaceuticals (The Netherlands)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: R&D collaboration
Action mechanism: antibody drug conjugate
Disease:
Details: * On March 26, 2015, Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery and testing of new therapeutic molecules to fight cancer and other serious illnesses with high unmet medical need, announced the signing of a 2 year-sponsored research program with Synthon Biopharmaceuticals, an international pharmaceutical company with highly focused development activities for new molecular entities in the therapeutic areas of oncology and autoimmune diseases.
The program aims at demonstrating the potent activity of a number of Synthon’s proprietary antibody-drug conjugates (ADCs), for multiple oncology targets.Synthon controls a unique technology position with respect to both the linker and drug components, and methods for conjugation to antibodies; these drugs are members of the class of duocarmycins having potency in the low picomolar range, which are suitable for maximizing the ADC\'s cell-killing potency. Oncodesign will dedicate to Synthon’s preclinical oncology programs a preferential access to all of Oncodesign’s internal and externally partnered technological platforms including cell lines assays, in vivo models, imaging and imaging-related capabilities. Synthon and Oncodesign had entered into a collaboration in 2011 for preclinical oncology research programs. The recently signed contract extends the collaboration to 2016.
Financial terms: Financial details haven\'t been disclosed.
Latest news:
